Table of Contents Author Guidelines Submit a Manuscript
Current Gerontology and Geriatrics Research
Volume 2010 (2010), Article ID 348174, 8 pages
http://dx.doi.org/10.1155/2010/348174
Review Article

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer

Oncology Department, Fondazione Poliambulanza, 25124 Brescia, Italy

Received 31 August 2009; Revised 14 March 2010; Accepted 7 April 2010

Academic Editor: Alexander Bürkle

Copyright © 2010 F. Meriggi and A. Zaniboni. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Google Scholar · View at Scopus
  2. M. J. Hayat, N. Howlader, M. E. Reichman, and B. K. Edwards, “Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program,” Oncologist, vol. 12, no. 1, pp. 20–37, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. National Cancer Institute, “SEER stage distribution by race, sex and age group for lung and bronchus cancer: SEER 9 Registries for 1988–2003,” http://seer.cancer.gov/faststats/index.php?site_Lung_and_%2520Bronchus_Cancer&stat_Survival.
  4. Non-Small Cell Lung Cancer Collaborative Group, “Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials,” British Medical Journal, vol. 311, no. 7010, pp. 899–909, 1995. View at Google Scholar
  5. K. Kelly, J. Crowley, P. A. Bunn Jr. et al., “Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial,” Journal of Clinical Oncology, vol. 19, no. 13, pp. 3210–3218, 2001. View at Google Scholar · View at Scopus
  6. J. H. Schiller, D. Harrington, C. P. Belani et al., “Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer,” The New England Journal of Medicine, vol. 346, no. 2, pp. 92–98, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. G. Pfister, D. H. Johnson, C. G. Azzoli et al., “American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003,” Journal of Clinical Oncology, vol. 22, no. 2, pp. 330–353, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. C. Gridelli, M. Aapro, A. Ardizzoni et al., “Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel,” Journal of Clinical Oncology, vol. 23, pp. 3125–3137, 2005. View at Google Scholar
  9. J. H. Lewis, M. L. Kilgore, D. P. Goldman et al., “Participation of patients 65 years of age or older in cancer clinical trials,” Journal of Clinical Oncology, vol. 21, no. 7, pp. 1383–1389, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. F. V. Fossella and C. Belani, “Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC): analyses in elderly patients,” Proceedings of the American Society of Clinical Oncology, vol. 22, p. 629a, 2003, abstract no. 2528. View at Google Scholar
  11. K. Kelly, S. Giarritta, W. Akerley et al., “Should older patients (Pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology trials 9509 and 9308,” Proceedings of the American Society of Clinical Oncology, vol. 20, p. 329a, 2001, abstract no. 1313. View at Google Scholar
  12. C. Langer, M. Vangel, J. Schiller et al., “Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (<70),” Proceedings of the American Society of Clinical Oncology, vol. 22, p. 639a, 2003, abstract no. 2571. View at Google Scholar
  13. C. Gridelli and F. A. Shepherd, “Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence,” Chest, vol. 128, no. 2, pp. 947–957, 2005. View at Publisher · View at Google Scholar · View at PubMed
  14. C. J. Langer, J. Manola, P. Bernardo et al., “Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of eastern cooperative oncology group 5592, a randomized trial,” Journal of the National Cancer Institute, vol. 94, no. 3, pp. 173–181, 2002. View at Google Scholar
  15. P. A. Bunn Jr. and R. Lilenbaum, “Chemotherapy for elderly patients with advanced non-small-cell lung cancer,” Journal of the National Cancer Institute, vol. 95, no. 5, pp. 341–343, 2003. View at Google Scholar
  16. T. Asmis, K. Ding, F. Shepherd et al., “Are age and co-morbidity prognostic factors in the treatment of metastatic non-small cell lung cancer (NSCLC): a review of a National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) randomized trial,” Lung Cancer, vol. 49, supplement 176, p. S85, 2005. View at Google Scholar
  17. V. Rusch, D. Klimstra, E. Venkatraman, P. W. T. Pisters, J. Langenfeld, and E. Dmitrovsky, “Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression,” Clinical Cancer Research, vol. 3, no. 4, pp. 515–522, 1997. View at Google Scholar
  18. J. Brabender, K. D. Danenberg, R. Metzger et al., “Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival,” Clinical Cancer Research, vol. 7, no. 7, pp. 1850–1855, 2001. View at Google Scholar
  19. S. S. Sridhar, L. Seymour, and F. A. Shepherd, “Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer,” Lancet Oncology, vol. 4, no. 7, pp. 397–406, 2003. View at Publisher · View at Google Scholar
  20. M. Fukuoka, S. Yano, G. Giaccone et al., “Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL trial),” Journal of Clinical Oncology, vol. 21, no. 12, pp. 2237–2246, 2003, Erratum in: Journal of Clinical Oncology, vol. 22, p. 4811, 2004. View at Publisher · View at Google Scholar · View at PubMed
  21. M. G. Kris, R. B. Natale, R. S. Herbst et al., “Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial,” Journal of the American Medical Association, vol. 290, no. 16, pp. 2149–2158, 2003. View at Publisher · View at Google Scholar · View at PubMed
  22. R. Pérez-Soler, A. Chachoua, L. A. Hammond et al., “Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 22, no. 16, pp. 3238–3247, 2004. View at Publisher · View at Google Scholar · View at PubMed
  23. G. Giaccone, “Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 14, pp. 3235–3242, 2005. View at Publisher · View at Google Scholar · View at PubMed
  24. N. Thatcher, A. Chang, P. Parikh et al., “Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer),” The Lancet, vol. 366, no. 9496, pp. 1527–1537, 2005. View at Publisher · View at Google Scholar · View at PubMed
  25. C. Schettino, M. A. Bareschino, V. Ricci, and F. Ciardiello, “Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment,” Expert Review of Respiratory Medicine, vol. 2, no. 2, pp. 167–178, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. C. Gridelli, P. Maione, V. Castaldo, and A. Rossi, “Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer,” British Journal of Cancer, vol. 89, no. 10, pp. 1827–1829, 2003. View at Publisher · View at Google Scholar · View at PubMed
  27. F. Cappuzzo, S. Bartolini, G. L. Ceresoli et al., “Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC),” British Journal of Cancer, vol. 90, no. 1, pp. 82–86, 2004. View at Publisher · View at Google Scholar · View at PubMed
  28. E. S. Kim, V. Hirsh, T. Mok et al., “Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial,” The Lancet, vol. 372, no. 9652, pp. 1809–1818, 2008. View at Publisher · View at Google Scholar
  29. L. Crinò, F. Cappuzzo, P. Zatloukal et al., “Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (invite): a randomized, phase II study,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4253–4260, 2008. View at Publisher · View at Google Scholar · View at PubMed
  30. T. S. Mok, Y.-L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” The New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at PubMed
  31. F. A. Shepherd, J. R. Pereira, T. Ciuleanu et al., “Erlotinib in previously treated non-small-cell lung cancer,” The New England Journal of Medicine, vol. 353, no. 2, pp. 123–132, 2005. View at Publisher · View at Google Scholar · View at PubMed
  32. P. Wheatley-Price, K. Ding, L. Seymour, G. M. Clark, and F. A. Shepherd, “Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21,” Journal of Clinical Oncology, vol. 26, no. 14, pp. 2350–2357, 2008. View at Publisher · View at Google Scholar · View at PubMed
  33. D. M. Jackman, B. Y. Yeap, N. I. Lindeman et al., “Phase II clinical trial of chemotherapy-naive patients 70 years of age treated with erlotinib for advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 25, no. 7, pp. 760–766, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. C. J. Langer, S. Li, J. Schiller, W. Tester, B. L. Rapoport, and D. H. Johnson, “Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in eastern cooperative oncology group performance status 2 non-small-cell lung cancer patients: ECOG 1599,” Journal of Clinical Oncology, vol. 25, no. 4, pp. 418–423, 2007. View at Publisher · View at Google Scholar · View at PubMed
  35. P. J. Hesketh, K. Chansky, D. H. M. Lau et al., “Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027),” Journal of Thoracic Oncology, vol. 1, no. 6, pp. 537–544, 2006. View at Publisher · View at Google Scholar
  36. C. J. Sweeney, J. Zhu, A. B. Sandler et al., “Outcome of patients with a performance status of 2 in eastern cooperative oncology group study E1594: a phase III trial in patients with metastatic nonsmall cell lung carcinoma,” Cancer, vol. 92, no. 10, pp. 2639–2647, 2001. View at Google Scholar
  37. R. Lilenbaum, R. Axelrod, S. Thomas et al., “Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 863–869, 2008. View at Publisher · View at Google Scholar · View at PubMed
  38. P. J. Hesketh, K. Chansky, A. J. Wozniak et al., “Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2,” Journal of Thoracic Oncology, vol. 3, no. 9, pp. 1026–1031, 2008. View at Publisher · View at Google Scholar · View at PubMed
  39. F. Cappuzzo, T. Ciuleanu, L. Stelmakh et al., “SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC,” Journal of Clinical Oncology, vol. 27, supplement 15, 2009, abstract no. 8001. View at Google Scholar
  40. V. A. Miller, P. O'Connor, C. Soh, and F. Kabbinavar, “A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC),” Journal of Clinical Oncology, vol. 27, supplement 18, 2009, abstract no. LBA 8002. View at Google Scholar
  41. C. Gridelli, C. Butts, F. Ciardiello, R. Feld, C. Gallo, and F. Perrone, “An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial,” Clinical Lung Cancer, vol. 9, no. 4, pp. 235–238, 2008. View at Publisher · View at Google Scholar · View at PubMed
  42. N. Hanna, F. A. Shepherd, F. V. Fossella et al., “Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1589–1597, 2004. View at Publisher · View at Google Scholar · View at PubMed
  43. F. A. Shepherd, J. R. Pereira, T. Ciuleanu et al., “Erlotinib in previously treated non-small-cell lung cancer,” The New England Journal of Medicine, vol. 353, no. 2, pp. 123–132, 2005. View at Publisher · View at Google Scholar · View at PubMed
  44. A. Bezjak, D. Tu, L. Seymour et al., “Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada clinical trials group study BR.21,” Journal of Clinical Oncology, vol. 24, no. 24, pp. 3831–3837, 2006. View at Publisher · View at Google Scholar · View at PubMed
  45. J.-Y. Douillard, “Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic nonsmall-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST),” in Proceedings of the 12th World Conference on Lung Cancer, Seoul, Korea, September 2007.
  46. Y. L. Wu, X.-N. Yang, and L.-J. Gu, “The characteristics of patients with non-small cell lung cancer with complete response treated with ZD1839,” in Proceedings of the Annual Meeting of the American Society of Clinical Oncology, Chicago, Ill, USA, June 2003, abstract no. 2770.
  47. R. S. Herbst, D. Prager, R. Hermann et al., “TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5892–5899, 2005. View at Publisher · View at Google Scholar · View at PubMed
  48. R. Pérez-Soler and L. Saltz, “Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5235–5246, 2005. View at Publisher · View at Google Scholar · View at PubMed
  49. D. A. Eberhard, B. E. Johnson, L. C. Amler et al., “Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5900–5909, 2005. View at Publisher · View at Google Scholar · View at PubMed
  50. U. Gatzemeier, A. Heller, D. Foernzler et al., “Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy ± erlotinib (TALENT),” in Proceedings of the Annual Meeting of the American Society of Clinical Oncology, Orlando, Fla, USA, May 2005, abstract no. 7028.
  51. M. Cobo, F. Cardenal, A. Insa et al., “Skin rash as surrogate marker of efficacy in patients with non-small cell lung cancer treated with erlotinib,” in Proceedings of the Annual Meeting of the American Society of Clinical Oncology, Chicago, Ill, USA, June 2007, abstract no. 7602.
  52. B. E. Johnson and P. A. Janne, “Epidermal growth factor receptor mutations in patients with non-small cell lung cancer,” Cancer Research, vol. 65, no. 17, pp. 7525–7529, 2005. View at Publisher · View at Google Scholar · View at PubMed
  53. G. Giaccone, “Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 14, pp. 3235–3242, 2005. View at Publisher · View at Google Scholar · View at PubMed
  54. H. Shigematsu, L. Lin, T. Takahashi et al., “Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers,” Journal of the National Cancer Institute, vol. 97, no. 5, pp. 339–346, 2005. View at Publisher · View at Google Scholar · View at PubMed
  55. G. J. Riely, W. Pao, D. Pham et al., “Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib,” Clinical Cancer Research, vol. 12, no. 3, pp. 839–844, 2006. View at Publisher · View at Google Scholar · View at PubMed
  56. D. M. Jackman, B. Y. Yeap, L. V. Sequist et al., “Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib,” Clinical Cancer Research, vol. 12, no. 13, pp. 3908–3914, 2006. View at Publisher · View at Google Scholar · View at PubMed
  57. F. R. Hirsch, W. A. Franklin, J. McCoy et al., “Predicting clinical benefit from EGFR TKIs: not all EGFR mutations are equal,” in Proceedings of the Annual Meeting of the American Society of Clinical Oncology, Atlanta, Ga, USA, June 2006, abstract no. 7072.
  58. L. R. Bailey, M. Kris, M. Wolf et al., “Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small cell lung cancer: IDEAL 1 and 2,” Proceedings of the American Association for Cancer Research, vol. 44, p. 1362, 2003, abstract no. LB-170. View at Google Scholar
  59. V. A. Miller, M. Zakowski, G. J. Riely et al., “EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma: results of a prospective phase II trial,” in Proceedings of the Annual Meeting of the American Society of Clinical Oncology, Atlanta, Ga, USA, June 2006, abstract no. 7003.
  60. V. M. Villaflor, L. Buckingham, M. Gale et al., “EGFR mutations (muts), IHC and FISH status, and chromosome 7 gene copy number combined with pAkt expression as potential predictors of survival in non-small cell lung cancer (NSCLC) patients (pts) treated with gefitinib (GEF),” in Proceedings of the Annual Meeting of the American Society of Clinical Oncology, Atlanta, Ga, USA, June 2006, abstract no. 7182.
  61. H. S. Parra, R. Cavina, F. Latteri et al., “Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer,” British Journal of Cancer, vol. 91, no. 2, pp. 208–212, 2004. View at Google Scholar
  62. S.-W. Han, P. G. Hwang, D. H. Chung et al., “Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer,” International Journal of Cancer, vol. 113, no. 1, pp. 109–115, 2005. View at Publisher · View at Google Scholar · View at PubMed
  63. F. Cappuzzo, F. R. Hirsch, E. Rossi et al., “Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer,” Journal of the National Cancer Institute, vol. 97, no. 9, pp. 643–655, 2005. View at Publisher · View at Google Scholar · View at PubMed
  64. M. S. Tzao, A. Sakurada, J. C. Cutz et al., “Erlotinib in lung cancer-molecular and clinical predictors of outcome,” The New England Journal of Medicine, vol. 353, pp. 133–144, 2005. View at Google Scholar
  65. F. R. Hirsch, M. Varella-Garcia, P. A. Bunn Jr. et al., “Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 5034–5042, 2006. View at Publisher · View at Google Scholar · View at PubMed
  66. T. Takano, Y. Ohe, H. Sakamoto et al., “Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 6829–6837, 2005. View at Publisher · View at Google Scholar · View at PubMed
  67. S. A. Ahrendt, P. A. Decker, E. A. Alawi et al., “Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung,” Cancer, vol. 92, no. 6, pp. 1525–1530, 2001. View at Google Scholar
  68. S. Rodenhuis, R. J. C. Slebos, A. J. M. Boot et al., “Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung,” Cancer Research, vol. 48, no. 20, pp. 5738–5741, 1988. View at Google Scholar
  69. Y. Suzuki, M. Orita, M. Shiraishi, K. Hayashi, and T. Sekiya, “Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products,” Oncogene, vol. 5, no. 7, pp. 1037–1043, 1990. View at Google Scholar
  70. M. Tsao, C. Zhu, A. Sakurada et al., “An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer,” in Proceedings of the Annual Meeting of the American Society of Clinical Oncology, Atlanta, Ga, USA, June 2006, abstract no. 7005.
  71. C. Gridelli, P. Maione, and A. Rossi, “Chemotherapy and targeted therapy for older patients with advanced non-small cell lung cancer,” in Educational Book, pp. 283–287, ASCO, 2009. View at Google Scholar
  72. C. Gridelli, “Treatment of advanced non-small-cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies,” Journal of Clinical Oncology, vol. 26, no. 1, pp. 13–15, 2008. View at Publisher · View at Google Scholar · View at PubMed
  73. L. P. Fried, C. M. Tangen, J. Walston et al., “Frailty in older adults: evidence for a phenotype,” Journals of Gerontology. Series A, vol. 56, no. 3, pp. M146–M156, 2001. View at Google Scholar
  74. C. J. Langer, “The “Lazarus response” in treatment-Naïve, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation,” Journal of Clinical Oncology, vol. 27, pp. 1350–1354, 2009. View at Google Scholar
  75. D. Cella, R. S. Herbst, T. J. Lynch et al., “Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial,” Journal of Clinical Oncology, vol. 23, no. 13, pp. 2946–2954, 2005. View at Publisher · View at Google Scholar · View at PubMed
  76. A. Inoue, K. Kobayashi, K. Usui et al., “First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1394–1400, 2009. View at Publisher · View at Google Scholar · View at PubMed
  77. C. Gridelli, P. Maione, D. Galetta, and A. Rossi, “Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure,” Journal of Thoracic Oncology, vol. 2, no. 1, pp. 96–98, 2007. View at Publisher · View at Google Scholar · View at PubMed
  78. C. Gridelli, A. Rossi, F. Mongillo, M. Bareschino, P. Maione, and F. Ciardiello, “A randomized phase II study of sorafenib/gemcitabine or sorafenih/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics,” Clinical Lung Cancer, vol. 8, no. 6, pp. 396–398, 2007. View at Publisher · View at Google Scholar